Anbio Biotechnology Class A (NNNN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Anbio Biotechnology Class A (NNNN) is down 67.1% since the beginning of the year. At $10 per share, NNNN is trading 82.0% below its 52-week high of $55.

Anbio Biotechnology Class A (NNNN) has returned -67.08% so far this year and -76.87% over the past 12 months.

Based on dividend-adjusted daily data since Feb 19, 2025, NNNN's average daily return is +0.53%, while the average monthly return is +17.93%. At this rate, an investment would double in approximately 0.4 years.

Historically, 61% of months were positive and 39% were negative. The best month was Jun 2025 with a return of +302.3%, while the worst month was Jun 2026 at -60.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 2 months.

On a daily basis, NNNN closed higher 51% of trading days. The best single day was Nov 5, 2025 with a return of +57.5%, while the worst single day was Oct 2, 2025 at -27.3%.

Anbio Biotechnology Class A has an annualized alpha of 265.01%, beta of 0.22, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 19, 2025.

• This stock captured 695.10% of S&P 500 Index gains and 287.12% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• Beta of 0.22 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NNNN ranks 14 for risk / return — above 14% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Anbio Biotechnology Class A. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Anbio Biotechnology Class A was 82.50%, occurring on Jul 15, 2026. The portfolio has not yet recovered.

The current Anbio Biotechnology Class A drawdown is 81.00%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Anbio Biotechnology Class A over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Anbio Biotechnology Class A is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.